和譽-B(02256.HK):於2025年AACR大會展示ABSK112(EGFR exon20ins)等四項最新突破性臨牀前研究成果
格隆匯4月28日丨和譽-B(02256.HK)發佈公告,其在2025年4月25日至4月30日於美國伊利諾伊州芝加哥舉行的2025年美國癌症研究協會大會上以壁報的形式發佈了四項最新突破性的臨牀前研究結果。該等研究成果包括EGFR exon20ins抑制劑 ABSK112、PRMT5*MTA抑制劑ABSK131以及pan-KRAS抑制劑ABK-KRAS-1,以及一項研究KRAS G12C抑制劑潛在耐藥機制的研究成果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.